SK4299A3 - A tablet contaning methanesulfonate of trovafloxacin - Google Patents

A tablet contaning methanesulfonate of trovafloxacin Download PDF

Info

Publication number: SK4299A3
Authority: SK; Slovakia
Prior art keywords: composition; weight; microcrystalline cellulose; trovafloxacin; methanesulfonate
Prior art date: 1998-01-21

Application number

SK42-99A

Other languages

English (en)

Slovak (sk)

Inventor

Dale Alton Johnson

Christopher Michael Sinko

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-14

Publication date

2000-06-12

1999-01-14 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2000-06-12 Publication of SK4299A3 publication Critical patent/SK4299A3/sk

Links

229960000497 trovafloxacin Drugs 0.000 title description 17
WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 title description 17
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title description 4
239000000203 mixture Substances 0.000 claims abstract description 61
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 37
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 37
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 37
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 37
DYNZICQDCVYXFW-AHZSKCOESA-N trovafloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F DYNZICQDCVYXFW-AHZSKCOESA-N 0.000 claims abstract description 28
239000000314 lubricant Substances 0.000 claims abstract description 11
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 37
235000019359 magnesium stearate Nutrition 0.000 claims description 19
229920002785 Croscarmellose sodium Polymers 0.000 claims description 13
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 13
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 13
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 13
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
239000007857 degradation product Substances 0.000 claims description 11
239000007884 disintegrant Substances 0.000 claims description 9
239000011248 coating agent Substances 0.000 claims description 8
238000000576 coating method Methods 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
239000000047 product Substances 0.000 claims description 8
239000007888 film coating Substances 0.000 claims description 6
238000009501 film coating Methods 0.000 claims description 6
238000000354 decomposition reaction Methods 0.000 claims description 5
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 4
238000013112 stability test Methods 0.000 claims description 4
238000004090 dissolution Methods 0.000 abstract description 20
239000003085 diluting agent Substances 0.000 abstract description 13
238000003860 storage Methods 0.000 abstract description 9
229960005021 trovafloxacin mesylate Drugs 0.000 abstract description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 12
238000000034 method Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
229960001681 croscarmellose sodium Drugs 0.000 description 9
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
230000014759 maintenance of location Effects 0.000 description 6
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
239000011230 binding agent Substances 0.000 description 5
235000013539 calcium stearate Nutrition 0.000 description 5
239000008116 calcium stearate Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
239000003086 colorant Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
229920003109 sodium starch glycolate Polymers 0.000 description 5
239000008109 sodium starch glycolate Substances 0.000 description 5
229940079832 sodium starch glycolate Drugs 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 4
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
235000011132 calcium sulphate Nutrition 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
229940045902 sodium stearyl fumarate Drugs 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000012937 correction Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000007908 dry granulation Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
239000004408 titanium dioxide Substances 0.000 description 3
239000000341 volatile oil Substances 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
239000002775 capsule Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000007922 dissolution test Methods 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000007654 immersion Methods 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000003643 water by type Substances 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
235000021537 Beetroot Nutrition 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
244000037364 Cinnamomum aromaticum Species 0.000 description 1
235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
241000207199 Citrus Species 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
235000003392 Curcuma domestica Nutrition 0.000 description 1
244000008991 Curcuma longa Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
240000005561 Musa balbisiana Species 0.000 description 1
235000018290 Musa x paradisiaca Nutrition 0.000 description 1
235000009421 Myristica fragrans Nutrition 0.000 description 1
244000270834 Myristica fragrans Species 0.000 description 1
240000005125 Myrtus communis Species 0.000 description 1
235000013418 Myrtus communis Nutrition 0.000 description 1
235000012550 Pimpinella anisum Nutrition 0.000 description 1
240000004760 Pimpinella anisum Species 0.000 description 1
241000758706 Piperaceae Species 0.000 description 1
229920001100 Polydextrose Polymers 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
235000014443 Pyrus communis Nutrition 0.000 description 1
240000001987 Pyrus communis Species 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000019568 aromas Nutrition 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
235000012730 carminic acid Nutrition 0.000 description 1
229940119201 cedar leaf oil Drugs 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000010630 cinnamon oil Substances 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000010634 clove oil Substances 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000003373 curcuma longa Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000280 densification Methods 0.000 description 1
QXYCYSAGHGKNHM-UHFFFAOYSA-N dodecyl octadecanoate;magnesium Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCC QXYCYSAGHGKNHM-UHFFFAOYSA-N 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000686 essence Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000000576 food coloring agent Substances 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
235000015201 grapefruit juice Nutrition 0.000 description 1
239000010903 husk Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
-1 hydroxypropyl Chemical group 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000005304 joining Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000004571 lime Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
239000001702 nutmeg Substances 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000001259 polydextrose Substances 0.000 description 1
235000013856 polydextrose Nutrition 0.000 description 1
229940035035 polydextrose Drugs 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000010670 sage oil Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000004513 sizing Methods 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
239000010678 thyme oil Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
235000013976 turmeric Nutrition 0.000 description 1
229920006163 vinyl copolymer Polymers 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK42-99A 1998-01-21 1999-01-14 A tablet contaning methanesulfonate of trovafloxacin SK4299A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7201398P	1998-01-21	1998-01-21

Publications (1)

Publication Number	Publication Date
SK4299A3 true SK4299A3 (en)	2000-06-12

Family

ID=22105016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK42-99A SK4299A3 (en)	1998-01-21	1999-01-14	A tablet contaning methanesulfonate of trovafloxacin

Country Status (34)

Country	Link
US (1)	US6187341B1 (fr)
EP (1)	EP0930068A3 (fr)
JP (1)	JPH11269072A (fr)
KR (1)	KR100314977B1 (fr)
CN (1)	CN1227743A (fr)
AP (1)	AP1094A (fr)
AR (1)	AR012780A1 (fr)
AU (1)	AU758381B2 (fr)
BG (1)	BG103106A (fr)
BR (1)	BR9900116A (fr)
CA (1)	CA2259698C (fr)
CO (1)	CO4810225A1 (fr)
DZ (1)	DZ2712A1 (fr)
EA (1)	EA003247B1 (fr)
GT (1)	GT199900004A (fr)
HR (1)	HRP990023A2 (fr)
HU (1)	HUP9900154A3 (fr)
ID (1)	ID23735A (fr)
IL (1)	IL128051A0 (fr)
IS (1)	IS4947A (fr)
MA (1)	MA24747A1 (fr)
NO (1)	NO990243L (fr)
NZ (1)	NZ333838A (fr)
OA (1)	OA10958A (fr)
PA (1)	PA8466701A1 (fr)
PE (1)	PE20000169A1 (fr)
PL (1)	PL330981A1 (fr)
SG (1)	SG70666A1 (fr)
SK (1)	SK4299A3 (fr)
TN (1)	TNSN99007A1 (fr)
TR (1)	TR199900089A3 (fr)
TW (1)	TW518224B (fr)
YU (1)	YU2399A (fr)
ZA (1)	ZA99393B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200101310T2 (tr) *	1998-11-10	2001-10-22	Bayer Aktiengesellschaft	Farmasötik moksifloksasin preparatı.
WO2001021211A2 (fr) *	1999-09-20	2001-03-29	Alza Corporation	Procede destine a reduire la transformation polymorphique d'un medicament
HU230030B1 (hu) *	1999-10-08	2015-05-28	Debiopharm International Sa	Fab I inhibitorok
FR2808441B1 (fr) *	2000-05-04	2004-06-18	Oreal	Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau
DE10031043A1 (de) *	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP1560584B1 (fr) *	2001-04-06	2009-01-14	Affinium Pharmaceuticals, Inc.	Inhibiteurs de fab i
EP1396263A1 (fr) *	2002-08-09	2004-03-10	Warner-Lambert Company	Compositions d'enrobage pour tablettes et caplets
EP1575951B1 (fr) *	2002-12-06	2014-06-25	Debiopharm International SA	Composes heterocycliques, procedes de production de ceux-ci et utilisation de ceux-ci dans un traitement
CN100415284C (zh) *	2002-12-30	2008-09-03	毛友昌	六味木香片的制备方法
WO2004082586A2 (fr)	2003-03-17	2004-09-30	Affinium Pharmaceuticals, Inc.	Compositions comportant plusieurs agents antibiotiques, et leurs procedes de mise en oeuvre
EP1459739B1 (fr) *	2003-03-19	2008-01-02	The Jordanian Pharmaceutical Manufacturing Co. Ltd.	Compositions pharmaceutiques non-hygroscopique contenant des acides carboxiliques quinilones non-hydratés
US8906413B2 (en)	2003-05-12	2014-12-09	Supernus Pharmaceuticals, Inc.	Drug formulations having reduced abuse potential
WO2005009395A2 (fr) *	2003-07-23	2005-02-03	L. Perrigo Company	Composition contenant des fibres cellulosiques
DK1828167T3 (da)	2004-06-04	2014-10-20	Debiopharm Int Sa	Acrylamidderivater som antibiotiske midler
ES2531735T3 (es) *	2004-10-15	2015-03-18	Supernus Pharmaceuticals, Inc.	Preparaciones farmacéuticas con menor potencial de abuso
KR20080075027A (ko) *	2005-12-05	2008-08-13	아피늄 파마슈티컬스, 인크.	Ｆａｂｉ 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
JP5468899B2 (ja)	2006-07-20	2014-04-09	アフィニウムファーマシューティカルズ，インク．	Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
EP2125802A4 (fr)	2007-02-16	2014-08-20	Debiopharm Int Sa	Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
AU2013279021C1 (en)	2012-06-19	2017-03-16	Debiopharm International Sa	Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
RS61312B1 (sr)	2016-02-26	2021-02-26	Debiopharm Int Sa	Lek za lečenje infekcija dijabetskog stopala
TN2021000159A1 (en)	2019-02-14	2023-04-04	Debiopharm Int Sa	Afabicin formulation, method for making the same and uses thereof
SG11202113174SA (en)	2019-06-14	2021-12-30	Debiopharm Int Sa	Medicament and use thereof for treating bacterial infections involving biofilm
JP2025529185A (ja) *	2022-08-30	2025-09-04	パンネックスセラピューティクスインコーポレイテッド	パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3601566A1 (de) *	1986-01-21	1987-07-23	Bayer Ag	Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en)	1986-01-21	1994-02-15	Bayer Aktiengesellschaft	Pharmaceutical formulations of ciprofloxacin
US4957554A (en)	1989-08-16	1990-09-18	Minnesota Mining And Manufacturing Company	Dimensionally-controlled ceramics
DE4120646A1 (de)	1991-06-22	1992-12-24	Bayer Ag	7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
WO1997007800A1 (fr) *	1995-08-29	1997-03-06	Pfizer Inc.	Formes zwitterioniques de trovafloxacine

1999
- 1999-01-11 PA PA19998466701A patent/PA8466701A1/es unknown
- 1999-01-13 EP EP99300258A patent/EP0930068A3/fr not_active Withdrawn
- 1999-01-14 AP APAP/P/1999/001443A patent/AP1094A/en active
- 1999-01-14 TR TR1999/00089A patent/TR199900089A3/tr unknown
- 1999-01-14 SK SK42-99A patent/SK4299A3/sk unknown
- 1999-01-14 IL IL12805199A patent/IL128051A0/xx unknown
- 1999-01-15 OA OA9900009A patent/OA10958A/en unknown
- 1999-01-15 ID IDP990036D patent/ID23735A/id unknown
- 1999-01-15 MA MA25433A patent/MA24747A1/fr unknown
- 1999-01-15 PE PE1999000036A patent/PE20000169A1/es not_active Application Discontinuation
- 1999-01-15 GT GT199900004A patent/GT199900004A/es unknown
- 1999-01-19 AR ARP990100191A patent/AR012780A1/es not_active Application Discontinuation
- 1999-01-19 IS IS4947A patent/IS4947A/is unknown
- 1999-01-19 JP JP11010298A patent/JPH11269072A/ja active Pending
- 1999-01-19 CA CA002259698A patent/CA2259698C/fr not_active Expired - Fee Related
- 1999-01-19 BR BR9900116-0A patent/BR9900116A/pt not_active IP Right Cessation
- 1999-01-20 NO NO990243A patent/NO990243L/no not_active Application Discontinuation
- 1999-01-20 KR KR1019990001589A patent/KR100314977B1/ko not_active Expired - Fee Related
- 1999-01-20 US US09/233,823 patent/US6187341B1/en not_active Expired - Fee Related
- 1999-01-20 SG SG1999000117A patent/SG70666A1/en unknown
- 1999-01-20 AU AU12173/99A patent/AU758381B2/en not_active Ceased
- 1999-01-20 YU YU2399A patent/YU2399A/sh unknown
- 1999-01-20 NZ NZ333838A patent/NZ333838A/xx unknown
- 1999-01-20 HU HU9900154A patent/HUP9900154A3/hu unknown
- 1999-01-20 TN TNTNSN99007A patent/TNSN99007A1/fr unknown
- 1999-01-20 DZ DZ990013A patent/DZ2712A1/fr active
- 1999-01-20 PL PL99330981A patent/PL330981A1/xx unknown
- 1999-01-20 CN CN99101232A patent/CN1227743A/zh active Pending
- 1999-01-20 ZA ZA9900393A patent/ZA99393B/xx unknown
- 1999-01-21 BG BG103106A patent/BG103106A/xx unknown
- 1999-01-21 CO CO99003190A patent/CO4810225A1/es unknown
- 1999-01-21 EA EA199900046A patent/EA003247B1/ru not_active IP Right Cessation
- 1999-01-21 TW TW088100897A patent/TW518224B/zh not_active IP Right Cessation
- 1999-01-21 HR HR60/072,013A patent/HRP990023A2/hr not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU1217399A (en)	1999-08-12
OA10958A (en)	2001-10-31
AR012780A1 (es)	2000-11-08
US6187341B1 (en)	2001-02-13
TR199900089A2 (xx)	1999-10-21
KR100314977B1 (ko)	2001-11-24
PL330981A1 (en)	1999-08-02
HUP9900154A2 (hu)	1999-09-28
NZ333838A (en)	2000-03-27
EP0930068A2 (fr)	1999-07-21
EA199900046A2 (ru)	1999-08-26
AP9901443A0 (en)	1999-03-31
MA24747A1 (fr)	1999-10-01
NO990243D0 (no)	1999-01-20
IL128051A0 (en)	1999-11-30
BG103106A (en)	1999-08-31
HUP9900154A3 (en)	2000-12-28
IS4947A (is)	1999-07-22
PA8466701A1 (es)	2000-09-29
BR9900116A (pt)	2000-05-02
ZA99393B (en)	2000-07-21
KR19990068014A (ko)	1999-08-25
NO990243L (no)	1999-07-22
YU2399A (sh)	2002-06-19
TW518224B (en)	2003-01-21
JPH11269072A (ja)	1999-10-05
SG70666A1 (en)	2000-02-22
CO4810225A1 (es)	1999-06-30
CN1227743A (zh)	1999-09-08
CA2259698C (fr)	2003-04-15
GT199900004A (es)	2000-07-08
ID23735A (id)	2000-05-11
EP0930068A3 (fr)	1999-12-22
TNSN99007A1 (fr)	2005-11-10
AU758381B2 (en)	2003-03-20
EA003247B1 (ru)	2003-02-27
PE20000169A1 (es)	2000-03-10
EA199900046A3 (ru)	1999-12-29
TR199900089A3 (tr)	1999-10-21
HRP990023A2 (en)	1999-08-31
DZ2712A1 (fr)	2003-09-01
AP1094A (en)	2002-08-19
CA2259698A1 (fr)	1999-07-21
HU9900154D0 (en)	1999-03-29

Publication	Publication Date	Title
SK4299A3 (en)	2000-06-12	A tablet contaning methanesulfonate of trovafloxacin
DE69825592T2 (de)	2005-08-11	Filmbeschichtungen und filmbeschichtungszusammensetzungen auf der basis von dextrin
EP2029134B1 (fr)	2011-07-27	Compositions pharmaceutiques stabilisées contenant de la fésotérodine
KR101774676B1 (ko)	2017-09-04	히드로모르폰 및 날록손을 포함하는 제약 조성물
HU227397B1 (en)	2011-05-30	Pharmaceutical formulations containing darifenacin
NO321615B1 (no)	2006-06-12	Farmasoytisk preparat for oral administrering av et N-piperidino-3-pyrazolkarboksyamidderivat, samt salter og solvater derav og fremgangsmate for fremstilling derav
EP1296685B1 (fr)	2007-02-28	Preparations a liberation prolongee a base d'antibiotiques de type quinolones et procede d'elaboration desdites preparations
DE60128263T2 (de)	2008-01-10	Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US5968553A (en)	1999-10-19	Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
HUE026040T2 (en)	2016-05-30	Formulations of SRC / ABL inhibitor
PL181470B1 (pl)	2001-07-31	Kompozycja o przedluzonym uwalnianiu cyzaprydu i sposób wytwarzania kompozycji o przedluzonym uwalnianiu cyzaprydu PL PL PL PL PL PL PL PL PL PL
DE60026481T2 (de)	2006-11-09	Wässriges filmbildendes Überzugsmittel und oral anzuwendende feste Arzneizubereitung
WO2018154395A2 (fr)	2018-08-30	Composition pharmaceutique à libération contrôlée de varénicline
DE112006001853T5 (de)	2008-05-15	Pharmazeutische Zusammensetzungen, die Clopidogrel-Bisulphat enthalten
EP1928441B1 (fr)	2013-02-27	Formulation à effet retard comprenant du 3-(2-diméthyleaminométhylecyclohexyle)phenol
CZ9399A3 (cs)	2000-06-14	Tableta obsahující methansulfonát trovafloxacinu
CN112641744B (zh)	2022-08-05	一种交沙霉素薄膜衣片及其制备方法
HK1019558A (en)	2000-02-18	Trovafloxacin mesylate tablet
DE10353832A1 (de)	2005-06-23	Feste pharmazeutische Zubereitungsform
DE202020106805U1 (de)	2021-04-19	Dosierungsformen mit verlängerter Freisetzung von Tapentadol-Phosphorsäuresalz